BOSTON--(BUSINESS WIRE)--Click to Tweet
Flex Pharma, Inc. (NASDAQ: FLKS), a biotechnology company developing innovative and proprietary treatments for nocturnal leg cramps (NLC), cramps and spasms associated with severe neuromuscular conditions such as MS and ALS, and exercise-associated muscle cramps, announced today that it will report its financial results for the second quarter ended June 30, 2016 on Wednesday, August 3, 2016 before the U.S. financial markets open.
